ACTR1B

Across TCGA pan-cancer cohorts, ACTR1B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACTR1B data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACTR1B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACTR1B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where ACTR1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.969	0.777	.004	50	view →
UCEC	DFS	Median	III,IV	0.386	1.000	.002	32	view →
PDAC	DFS	Quartile	All	0.473	0.274	.009	5	view →
HNSC	DFS	Tertile	III,IV	0.936	0.693	.007	5	view →
LUAD	DFS	Quartile	All	1.000	0.593	.014	3	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACTR1B–CCRCC (DFS)

Open the CCRCC breakdown →